Big Pharma Talks Deal-Making with Biotechs and Academia
By Nuala Moran
Thursday, June 30, 2011
WASHINGTON Here's a new mantra, and possibly a new discipline, for biotechs looking to do deals with pharma: Be tentacular. That is the advice of Shaun Grady, head of strategic partnering and business development at AstraZeneca plc, who described how the UK pharma company turned down the offer to license Nektar Inc.'s NKTR-118, a Phase III compound for treating opioid-induced constipation, on "two or three occasions."
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.